REVA Medical
REVA Medical is a leader in bioresorbable polymer technologies for vascular applications, known for its innovative products like the MOTIV Bioresorbable Scaffold and Fantom Encore, which are designed to treat peripheral artery disease and improve patient outcomes.
Company Overview
REVA Medical is a pioneer in the field of bioresorbable polymer technologies, focused on vascular applications. The company's mission is to enhance patient health through the use of biomaterials in the development and sale of implantable medical devices. Headquartered at 5751 Copley Drive, San Diego, CA 92111, REVA Medical has a 20-year history during which it has developed 19 polymer families.
Innovative Products
REVA Medical offers several cutting-edge products, including the MOTIV Bioresorbable Scaffold, TyroSphere beads, and Fantom Encore. The MOTIV Scaffold is tailored for treating below-the-knee peripheral artery disease and uses Tyrocore™, the company's proprietary polymer. The TyroSphere beads are bioresorbable embolic microspheres for hypervascular tumors, with advantages such as safe degradation and radiopacity. Fantom Encore is a third-generation bioresorbable scaffold providing advanced features like ease-of-use and the thinnest struts among CE Mark BRS.
Technology and Innovations
REVA Medical leverages its proprietary polymer, Tyrocore™, in its suite of implantable bioresorbable medical devices. Tyrocore™ allows for features such as radiopacity and bioresorption, which contribute to the advanced functionality of products like Fantom Encore and MOTIV. The company's innovations are aimed at supporting arteries during the healing process and then disappearing, thereby enabling natural movement and function to return to the artery.
Regulatory Approvals
REVA Medical's MOTIV Bioresorbable Scaffold is the first of its kind to gain CE Mark approval for below-the-knee peripheral artery disease and has received FDA Breakthrough Technology Status in the US. This regulatory approval underscores the reliability and advanced nature of REVA's technology in the treatment of vascular diseases.
Clinical Programs
REVA Medical maintains a significant clinical program, highlighted by the FANTOM II trial, which has demonstrated excellent clinical performance over a two-year period. This trial is part of REVA's commitment to providing clinical evidence and advancing physician education, aimed at fostering progress in the field of bioresorbable scaffolds. Fantom Encore, a key product in this program, is noted for improving procedural accuracy and ease-of-use.